SUVENPHAR2021-01-012021-03-31in-bse-fin:OneOperatingExpenses01Member SUVENPHAR2021-01-012021-03-31in-bse-fin:OneOperatingExpenses02Member SUVENPHAR2021-01-012021-03-31in-bse-fin:OneOperatingExpenses03Member SUVENPHAR2021-01-012021-03-31in-bse-fin:FourOperatingExpenses01Member SUVENPHAR2021-01-012021-03-31in-bse-fin:FourOperatingExpenses02Member SUVENPHAR2021-01-012021-03-31in-bse-fin:FourOperatingExpenses03Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares SUVENPHAR 2020-04-01 2021-03-31 2021-06-01 INR Lakhs Yearly true Cash Flow Indirect Single segment Contract Development and ManufacturingnOperations (CDMO) 2021-01-01 2021-03-31 Unaudited Standalone 2591648000.00 32982000.00 2624630000.00 873746000.00 0.00 39828000.00 165127000.00 18703000.00 83147000.00 576020000.00 1756571000.00 868059000.00 0.00 868059000.00 183465000.00 40073000.00 223538000.00 0.00 644521000.00 0.00 0.00 0.00 0.00 644521000.00 -2235000.00 642286000.00 0.00 0.00 254565000.00 1 2.53 2.53 0.00 0.00 2.53 2.53 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 8th June, 2021. The results for the year ended March 31, 2021 has been audited and for the quarter ended March 31,2021 has been reviewed by the statutory auditors of the company. 2) The Board has recommended a final dividend of Rs.1.00 per share (i.e @100% on paid up one equity share of Rs.1.00 each) for the financial year 2020-21 subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM) of the company. This final dividend is in addition to the Interim dividend of Rs.1.00 per share (100% of one equity share) already paid. With this final dividend the total dividend for the year 2020-21 would be Rs.2.00 per share ( i.e 200% on paid up one equity share). 3) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 4) The consolidated financial results include the results of the wholly owned subsidiary Suven Pharma, Inc and Associate Rising Pharma Holdings, Inc 5) The Board has allotted the Bonus shares at 1:1 ratio in it's Board meeting held on 29th September, 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956. In order to maintain uniformity and comparabiity the EPS of previous periods have been restated. The paidup capital on account of Bonus issue of Rs.1272.82 lakhs has been appropriated from Share premium account. 6) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. 7) The National Company Law Tribunal, Hyderabad Bench vide its order dated January 06,2020 has approved the scheme of arrangement for demerger of CRAMS undertaking of the Suven Life Sciences Limited (SLSL) to Suven Pharmaceuticals Limited (SPL) with effect from October 01, 2018 (the appointed date). The Scheme became effective from October 01, 2018. Pursuant to the Scheme, all the assets, liabilities, income and expenses of the CRAMS undertaking have been transferred to SPL from the appointed date. 8) The COVID-19 did have some impact on the business and research operations in India starting March 2021 and continues to impact in terms of employee absenteeism (around 20%), adjustment of shifts due to lock down, material movements and increase in raw material and logistics cost due to shortage of oxygen. However, there was no major impact on our subsidiary, Suven Pharma, Inc., USA. 9) Pursuant to a fire accident on 26th April, 2020 at Jeedimetla Plant, certain fixed assets and other contents in building was damaged. The company has lodged an initial estimate of loss with insurance company and survey is currently ongoing. During the period ended 31st March 2021, the company has written off net book value of assets aggregating Rs 128.80 Lakhs and recognised a minimum insurance claim receivable for equivalent amount. 10) The figures for the current quarter and quarter ended March 31, 2020 are the balancing figures between the audited figures inrespect of full financeial year ended March 31.2021 and March 31, 2020, respectively and published year to date figures upto 3rd quarter ended 31st December 2020 and 31st december 2019, respectively, regrouped as necessary. Single segment 2020-04-01 2021-03-31 Audited Standalone 10097185000.00 142370000.00 10239555000.00 3103150000.00 0.00 -83730000.00 762330000.00 91437000.00 316358000.00 1910218000.00 6099763000.00 4139792000.00 0.00 4139792000.00 1017151000.00 36172000.00 1053323000.00 0.00 3086469000.00 0.00 0.00 0.00 0.00 3086469000.00 -8370000.00 3078099000.00 0.00 0.00 254565000.00 1 10397268000.00 12.12 12.12 0.00 0.00 12.12 12.12 Manufacturing Expenses 446831000.00 Other Expenses 114126000.00 R & D Expenses 15063000.00 Manufacturing Expenses 1337894000.00 Other Expenses 461749000.00 R & D Expenses 110575000.00 91437000.00 -262082000.00 133608000.00 0.00 -126992000.00 -7895000.00 0.00 0.00 0.00 119452000.00 0.00 -16448000.00 0.00 312207000.00 0.00 -10278000.00 -16686000.00 65428000.00 8912000.00 -9756000.00 0.00 2679000.00 0.00 -33277000.00 0.00 0.00 7216000.00 -335000.00 0.00 251832000.00 4391624000.00 0.00 0.00 0.00 1094358000.00 0.00 3297266000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 336000.00 1108460000.00 -1465928000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2543000.00 0.00 -2576595000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 123017000.00 547265000.00 0.00 0.00 254565000.00 89236000.00 0.00 2520000.00 -765529000.00 -44858000.00 4000.00 -44854000.00 115768000.00 70914000.00